http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3743424-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dca0fbe025876cd4f7a788dd4bed1824 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d67d8a043b86c88cdd7759121f41322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_960ce80fed82e8a02f0065ac1dcee75a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb7aa4d8f7a0e4b85217d8c30eb6ea73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c9c74cc92852de4ca7690599e7b0138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f7d9c26fce4dab31a35d207b00e9e51 |
| publicationDate | 2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3743424-A1 |
| titleOfInvention | Cap-dependent endonuclease inhibitors |
| abstract | Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof; wherein Formula (I): A 1 is CR 4 or N; A 2 is CR 5 ' R 6 'or NR 7 ' ; A 3 is CR 5 ' R 6 'or NR 7 '; each of R 1 , R 2 , R 2 ', R 3 , R 3 ', R 4 , R 5 , R 5 ', R 6 , R 6 ', R 7 , and R 7 ', independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylamine, C 3-20 carbocyclyl, or C 3-20 heterocyclyl; or R 5 and R 6 , R 5 ' and R 6 ', or R 5 and R 5 ', together with the adjacent atom to which they are each attached, form C 3-10 carbocyclyl or C 3-10 heterocyclyl. Further provided are a method of using the above- described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same. |
| priorityDate | 2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.